<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202185</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190940</org_study_id>
    <secondary_id>2019-A02968-49</secondary_id>
    <nct_id>NCT04202185</nct_id>
  </id_info>
  <brief_title>Evaluation of a Cohort of Congenital Deep Deafness Patients and/or With Auditory Neuropathy, Looking for DFNB9</brief_title>
  <acronym>AUDIOFERLINE</acronym>
  <official_title>Evaluation of a Cohort of Congenital Deep Deafness Patients and/or With Auditory Neuropathy, Looking for DFNB9</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of a cohort of deaf children looking for autosomal recessive deafness-9 (DFNB9).

      Clinical and audiologic evaluation of patients with known auditive neuropathy / auditory
      dys-synchrony (ANAD) or recently diagnosed congenital severe to profound hearing loss (HL),
      and assessing genetic analysis looking for DFNB9. The investigators expect to compile
      genotypic and phenotypic characterization of 25 children with DFNB9 within 4 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ANAD is not a rare type of hearing loss. Nevertheless, its profile is heterogeneous and the
      pathology remain underdiagnosed. The investigators will screen all new patients with
      bilateral severe to profound HL, looking for DFNB9. They will analyse their electrophysiology
      (auditory potential, and otoacoustic emission), and their audio-vestibular profile, at an
      early stage and one year after inclusion. All patients will be seen in the genetic clinic.
      Also, the investigators will analyse all patients with ANAD profile and patients known with
      ANAD.

      All informations will provide precise data base to allow a better understanding of the
      pathology. It might also lead to select the best candidates for future gene therapy
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of deafness caused by DFNB9</measure>
    <time_frame>3 months</time_frame>
    <description>Prevalence and type of bi-allelic pathogenic changes Otoferlin Molecular analysis will be done by Next Generation Sequencing Capture method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Audiological characteristics in free fields at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>audiometric thresholds on 500, 1000, 2000, 4000 Hz in free fields</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Audiological characteristics in separate ears at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>audiometric thresholds on 500, 1000, 2000, 4000 Hz in separate ears</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Audiological characteristics in free fields at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>audiometric thresholds on 500, 1000, 2000, 4000 Hz in free fields</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Audiological characteristics in separate ears at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>audiometric thresholds on 500, 1000, 2000, 4000 Hz in separate ears</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological characteristics : auditory evoked potentials (PEA) at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>PEA thresholds per ear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological characteristics : auditory evoked potentials (PEA) at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>PEA thresholds per ear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological characteristics : auditory Steady State Response (ASSR) at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>ASSR thresholds per ear at 500, 1000, 2000, 4000 Hz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological characteristics : auditory Steady State Response (ASSR) at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>ASSR thresholds per ear at 500, 1000, 2000, 4000 Hz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological characteristics : otoacoustic emissions (OEAs) at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>OEAs status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological characteristics : otoacoustic emissions (OEAs) at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>OEAs status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vestibular characteristics : per-oral endoscopic myotomy (PEOM) at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>PEOM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vestibular characteristics : per-oral endoscopic myotomy (PEOM) at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>PEOM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vestibular characteristics : video Head Impulse Test (VHIT) at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>VHIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vestibular characteristics : video Head Impulse Test (VHIT) at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>VHIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caloric Tests at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>Caloric Tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caloric Tests at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>Caloric Tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical development scale at diagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>For child under 3 years with : walk age, sitting age and head held age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical development scale at 12 months or last record</measure>
    <time_frame>12 months</time_frame>
    <description>For child under 3 years with : walk age, sitting age and head held age</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Congenital Profound Hearing Loss</condition>
  <arm_group>
    <arm_group_label>G1a</arm_group_label>
    <description>infants under 3 years deaf severe to deep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G1b</arm_group_label>
    <description>children under 16 years of age with audiologically proven auditory neuropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G2</arm_group_label>
    <description>patients &lt;25 years old with one or two Otoferlin mutations</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Retrospective collection data from diagnostic Data collected following to medical exam as part of care</description>
    <arm_group_label>G1a</arm_group_label>
    <arm_group_label>G1b</arm_group_label>
    <arm_group_label>G2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic analysis</intervention_name>
    <description>Research of mutation and identification of genetic panel as part of care</description>
    <arm_group_label>G1a</arm_group_label>
    <arm_group_label>G1b</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient coming to the Necker Hospital for a deafness visit or for a check-up prior to a
        cochlear implantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        G1a / Inclusion Criteria:

          -  Child from 0 to 3 years old

          -  Child with severe to profound bilateral deafness newly diagnosed with:

          -  Average hearing threshold&gt; 90 decibel on each ear and / or no response to 90 decibel
             PEA on each ear

          -  And No response to ASSR

        G1b / Inclusion Criteria:

          -  Child under 16

          -  Child with newly diagnosed hearing neuropathy : tonal/vocal dissociation (when this is
             possible), and/or modified PEA, and/or discordant ASSR, and/or OEA present.

        G2 / Inclusion Criteria:

          -  Adult patient under 25 or child

          -  Patient with deafness with auditory neuropathy

          -  Patient known to have 1 or 2 mutations of the otoferlin protein

        Exclusion Criteria:

          -  Other type of deafness such as : unilateral deafness, deafness of transmission,
             malformation syndrome, known familial deafness other than auditory neuropathy.

          -  Patient without medical insurance

          -  Lack of consent to DNA sampling, of one or both biological parents (consent of the
             care)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie LOUNDON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie LOUNDON, MD</last_name>
    <phone>+33 1 71 39 67 82</phone>
    <email>natalie.loundon@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure CHOUPEAUX, Master</last_name>
    <phone>+33 1 44 38 17 11</phone>
    <email>laure.choupeaux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unité d'Audiophonologie et d'Implantation cochléaire - Necker hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie LOUNDON, MD</last_name>
      <phone>+33 1 71 39 67 82</phone>
      <email>nathalie.loundon@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Denoyelle F, Petit C. DFNB9. Adv Otorhinolaryngol. 2002;61:142-4.</citation>
    <PMID>12408076</PMID>
  </reference>
  <reference>
    <citation>Loundon N, Marcolla A, Roux I, Rouillon I, Denoyelle F, Feldmann D, Marlin S, Garabedian EN. Auditory neuropathy or endocochlear hearing loss? Otol Neurotol. 2005 Jul;26(4):748-54.</citation>
    <PMID>16015179</PMID>
  </reference>
  <reference>
    <citation>Marlin S, Feldmann D, Nguyen Y, Rouillon I, Loundon N, Jonard L, Bonnet C, Couderc R, Garabedian EN, Petit C, Denoyelle F. Temperature-sensitive auditory neuropathy associated with an otoferlin mutation: Deafening fever! Biochem Biophys Res Commun. 2010 Apr 9;394(3):737-42. doi: 10.1016/j.bbrc.2010.03.062. Epub 2010 Mar 16.</citation>
    <PMID>20230791</PMID>
  </reference>
  <reference>
    <citation>Mehl AL, Thomson V. The Colorado newborn hearing screening project, 1992-1999: on the threshold of effective population-based universal newborn hearing screening. Pediatrics. 2002 Jan;109(1):E7.</citation>
    <PMID>11773575</PMID>
  </reference>
  <reference>
    <citation>Migliosi V, Modamio-Høybjør S, Moreno-Pelayo MA, Rodríguez-Ballesteros M, Villamar M, Tellería D, Menéndez I, Moreno F, Del Castillo I. Q829X, a novel mutation in the gene encoding otoferlin (OTOF), is frequently found in Spanish patients with prelingual non-syndromic hearing loss. J Med Genet. 2002 Jul;39(7):502-6.</citation>
    <PMID>12114484</PMID>
  </reference>
  <reference>
    <citation>Rouillon I, Marcolla A, Roux I, Marlin S, Feldmann D, Couderc R, Jonard L, Petit C, Denoyelle F, Garabédian EN, Loundon N. Results of cochlear implantation in two children with mutations in the OTOF gene. Int J Pediatr Otorhinolaryngol. 2006 Apr;70(4):689-96. Epub 2005 Oct 13.</citation>
    <PMID>16226319</PMID>
  </reference>
  <reference>
    <citation>Roux I, Safieddine S, Nouvian R, Grati M, Simmler MC, Bahloul A, Perfettini I, Le Gall M, Rostaing P, Hamard G, Triller A, Avan P, Moser T, Petit C. Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell. 2006 Oct 20;127(2):277-89.</citation>
    <PMID>17055430</PMID>
  </reference>
  <reference>
    <citation>Varga R, Avenarius MR, Kelley PM, Keats BJ, Berlin CI, Hood LJ, Morlet TG, Brashears SM, Starr A, Cohn ES, Smith RJ, Kimberling WJ. OTOF mutations revealed by genetic analysis of hearing loss families including a potential temperature sensitive auditory neuropathy allele. J Med Genet. 2006 Jul;43(7):576-81. Epub 2005 Dec 21.</citation>
    <PMID>16371502</PMID>
  </reference>
  <reference>
    <citation>Yasunaga S, Grati M, Cohen-Salmon M, El-Amraoui A, Mustapha M, Salem N, El-Zir E, Loiselet J, Petit C. A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. Nat Genet. 1999 Apr;21(4):363-9.</citation>
    <PMID>10192385</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Auditory neuropathy</keyword>
  <keyword>DFNB9</keyword>
  <keyword>Children</keyword>
  <keyword>Hearing loss</keyword>
  <keyword>Deafness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

